المؤلفون: Niramol Savaraj, Giora M. Mavligit, Robert S. Benjamin, William S. Fields, M. Andrew Burgess, Sidney Wallace, Rosa A. Tang, Milam E. Leavens, Carl Plager, Lynn G. Feun, Wai-Kwan A. Yung, Y. Y. Lee, Richard P. Moser

المصدر: Cancer Drug Delivery. 1:239-245

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, Cranial radiation, Drug Administration Schedule, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Infusions, Intra-Arterial, In patient, Aged, Pharmacology, Cisplatin, Brain Neoplasms, business.industry, Middle Aged, Carmustine, Surgery, Carotid Arteries, cardiovascular system, Drug Evaluation, Female, business, medicine.drug

الوصف: Eighteen patients with progressive or recurrent intracerebral malignant neoplasms after cranial radiation therapy were entered in a phase-I trial of intracarotid bis-chloroethylnitrosourea (BCNU) and cisplatin. Thirty-six courses of varying doses of BCNU and cisplatin were infused intraarterially via a percutaneous, trasfemoral approach. Courses were repeated every 4-6 weeks upon patients' recovery from toxicity. Intraarterial cisplatin or BCNU alone was administered if the blood counts were still subnormal. CT scans and neurologic examinations were performed monthly. Major toxic effects included ipsilateral retinal (amaurosis) in 4 patients and neurologic toxicity in 2 patients (minor focal seizure, reversible obtundation in one patient, and transient hemiparesis in one patient). One patient was infused by a catheter inserted into the supraclinoid internal carotid artery and had no further visual deterioration and no major side effects. Tumor regression was observed in patients previously treated with radiation and/or systemic chemotherapy, including 4 of 9 who had recurrent malignant gliomas, and 2 of 9 who had metastatic tumors. Recommended dose for phase-II trials is BCNU 100 mg/m2 and cisplatin 60 mg/m2 every 4-6 weeks. Retinal and neurologic toxicity are possible side effects.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d496006d1a84291086932122fec94a03Test
https://doi.org/10.1089/cdd.1984.1.239Test

المؤلفون: Niramol Savaraj, ya Yen Lee, Sidney Wallace, Lynn G. Feun, C. Charnsangavej, Rosa A. Tang, W. k.Alfred Yung

المصدر: Cancer Drug Delivery. 3:147-156

مصطلحات موضوعية: Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Urology, Recurrent Glioma, Leukoencephalopathy, Lethargy, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Infusions, Intra-Arterial, Aged, Pharmacology, Cisplatin, Chemotherapy, Carmustine, Brain Neoplasms, business.industry, Cancer, Middle Aged, medicine.disease, Combined Modality Therapy, Carotid Arteries, Hemiparesis, Anesthesia, Drug Evaluation, Female, medicine.symptom, business, Carotid Artery, Internal, medicine.drug

الوصف: Intracarotid BCNU (100 mg/m2) and cisplatin (60 mg/m2) were administered to 36 patients with malignant brain tumors recurrent or progressive after cranial irradiation. Courses of therapy were repeated at 4-6 week intervals. Of 23 evaluable patients with recurrent glioma, 9 (39%) had tumor regression by CT scan and 3 had stable disease. The median time to tumor progression for responding patients was 37 weeks. For all patients with primary tumors it was 14 weeks. Six of 9 patients with no prior chemotherapy had a response and 1 had stable disease. Of 14 patients who had received prior chemotherapy, 3 had a response and 2 had stable disease. Survival ranged from 9 weeks to 95+ weeks (median 34 weeks) from start of therapy. Six of 23 patients with primary tumors are alive 1 year or more following therapy. Four of 11 patients with brain metastases had a response and 2 had stable disease. Major neurologic toxicity of intracarotid BCNU and cisplatin appeared cumulative and consisted of reversible hemiparesis in 3% of 118 courses, TIA in 1%, expressive aphasia in 9%, lethargy in 3%, seizures in 12%, and reversible confusion in 1%. Retinal toxicity consisted of mild blurring of vision in 4 patients and ipsilateral blindness in 5 patients. Three of 22 patients who had received supraophthalmic infusion later developed evidence of leukoencephalopathy. Intracarotid BCNU and cisplatin appears to have modest increase in activity over intracarotid cisplatin alone (Cancer 54:794, 1984), however, neurologic and retinal toxicity may also be increased.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4af5334e8ad64a1aeb1c224f8fc9a89eTest
https://doi.org/10.1089/cdd.1986.3.147Test